Skip to main content
Top
Published in: Diabetologia 11/2010

01-11-2010 | Article

Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance

Authors: V. B. Matthews, T. L. Allen, S. Risis, M. H. S. Chan, D. C. Henstridge, N. Watson, L. A. Zaffino, J. R. Babb, J. Boon, P. J. Meikle, J. B. Jowett, M. J. Watt, J.-O. Jansson, C. R. Bruce, M. A. Febbraio

Published in: Diabetologia | Issue 11/2010

Login to get access

Abstract

Aims/hypothesis

The role of IL-6 in the development of obesity and hepatic insulin resistance is unclear and still the subject of controversy. We aimed to determine whether global deletion of Il6 in mice (Il6 −/−) results in standard chow-induced and high-fat diet (HFD)-induced obesity, hepatosteatosis, inflammation and insulin resistance.

Methods

Male, 8-week-old Il6 −/− and littermate control mice were fed a standard chow or HFD for 12 weeks and phenotyped accordingly.

Results

Il6 −/− mice displayed obesity, hepatosteatosis, liver inflammation and insulin resistance when compared with control mice on a standard chow diet. When fed a HFD, the Il6 −/− and control mice had marked, equivalent gains in body weight, fat mass and ectopic lipid deposition in the liver relative to chow-fed animals. Despite this normalisation, the greater liver inflammation, damage and insulin resistance observed in chow-fed Il6 −/− mice relative to control persisted when both were fed the HFD. Microarray analysis from livers of mice fed a HFD revealed that genes associated with oxidative phosphorylation, the electron transport chain and tricarboxylic acid cycle were uniformly decreased in Il6 −/− relative to control mice. This coincided with reduced maximal activity of the mitochondrial enzyme β-hydroxyacyl-CoA-dehydrogenase and decreased levels of mitochondrial respiratory chain proteins.

Conclusions/interpretation

Our data suggest that IL-6 deficiency exacerbates HFD-induced hepatic insulin resistance and inflammation, a process that appears to be related to defects in mitochondrial metabolism.
Appendix
Available only for authorised users
Literature
2.
go back to reference Carey AL, Bruce CR, Sacchetti M et al (2004) Interleukin-6 and tumor necrosis factor-alpha are not increased in patients with type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness. Diabetologia 47:1029–1037PubMed Carey AL, Bruce CR, Sacchetti M et al (2004) Interleukin-6 and tumor necrosis factor-alpha are not increased in patients with type 2 diabetes: evidence that plasma interleukin-6 is related to fat mass and not insulin responsiveness. Diabetologia 47:1029–1037PubMed
4.
go back to reference Pedersen BK, Febbraio MA (2008) Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 88:1379–1406CrossRefPubMed Pedersen BK, Febbraio MA (2008) Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol Rev 88:1379–1406CrossRefPubMed
5.
go back to reference Al-Khalili L, Bouzakri K, Glund S, Lonnqvist F, Koistinen HA, Krook A (2006) Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Mol Endocrinol 20:3364–3375CrossRefPubMed Al-Khalili L, Bouzakri K, Glund S, Lonnqvist F, Koistinen HA, Krook A (2006) Signaling specificity of interleukin-6 action on glucose and lipid metabolism in skeletal muscle. Mol Endocrinol 20:3364–3375CrossRefPubMed
6.
go back to reference Bruce CR, Dyck DJ (2004) Cytokine regulation of skeletal muscle fatty acid metabolism: effect of interleukin-6 and tumor necrosis factor-alpha. Am J Physiol Endocrinol Metab 287:E616–E621CrossRefPubMed Bruce CR, Dyck DJ (2004) Cytokine regulation of skeletal muscle fatty acid metabolism: effect of interleukin-6 and tumor necrosis factor-alpha. Am J Physiol Endocrinol Metab 287:E616–E621CrossRefPubMed
7.
go back to reference Carey AL, Steinberg GR, Macaulay SL et al (2006) Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 55:2688–2697CrossRefPubMed Carey AL, Steinberg GR, Macaulay SL et al (2006) Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase. Diabetes 55:2688–2697CrossRefPubMed
8.
go back to reference Glund S, Deshmukh A, Long YC et al (2007) Interleukin-6 directly increases glucose metabolism in resting human skeletal muscle. Diabetes 56:1630–1637CrossRefPubMed Glund S, Deshmukh A, Long YC et al (2007) Interleukin-6 directly increases glucose metabolism in resting human skeletal muscle. Diabetes 56:1630–1637CrossRefPubMed
9.
go back to reference Petersen EW, Carey AL, Sacchetti M et al (2005) Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. Am J Physiol Endocrinol Metab 288:E155–E162CrossRefPubMed Petersen EW, Carey AL, Sacchetti M et al (2005) Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. Am J Physiol Endocrinol Metab 288:E155–E162CrossRefPubMed
10.
go back to reference Rotter Sopasakis V, Larsson BM, Johansson A, Holmang A, Smith U (2004) Short-term infusion of interleukin-6 does not induce insulin resistance in vivo or impair insulin signalling in rats. Diabetologia 47:1879–1887CrossRefPubMed Rotter Sopasakis V, Larsson BM, Johansson A, Holmang A, Smith U (2004) Short-term infusion of interleukin-6 does not induce insulin resistance in vivo or impair insulin signalling in rats. Diabetologia 47:1879–1887CrossRefPubMed
11.
go back to reference Yuen DY, Dwyer RM, Matthews VB et al (2009) Interleukin-6 attenuates insulin-mediated increases in endothelial cell signaling but augments skeletal muscle insulin action via differential effects on tumor necrosis factor-alpha expression. Diabetes 58:1086–1095CrossRefPubMed Yuen DY, Dwyer RM, Matthews VB et al (2009) Interleukin-6 attenuates insulin-mediated increases in endothelial cell signaling but augments skeletal muscle insulin action via differential effects on tumor necrosis factor-alpha expression. Diabetes 58:1086–1095CrossRefPubMed
12.
go back to reference Kim HJ, Higashimori T, Park SY et al (2004) Differential effects of interleukin-6 and 10 on skeletal muscle and liver insulin action in vivo. Diabetes 53:1060–1067CrossRefPubMed Kim HJ, Higashimori T, Park SY et al (2004) Differential effects of interleukin-6 and 10 on skeletal muscle and liver insulin action in vivo. Diabetes 53:1060–1067CrossRefPubMed
13.
go back to reference Klover PJ, Zimmers TA, Koniaris LG, Mooney RA (2003) Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52:2784–2789CrossRefPubMed Klover PJ, Zimmers TA, Koniaris LG, Mooney RA (2003) Chronic exposure to interleukin-6 causes hepatic insulin resistance in mice. Diabetes 52:2784–2789CrossRefPubMed
14.
go back to reference Holmes AG, Mesa JL, Neill BA et al (2008) Prolonged interleukin-6 administration enhances glucose tolerance and increases skeletal muscle PPARalpha and UCP2 expression in rats. J Endocrinol 198:367–374CrossRefPubMed Holmes AG, Mesa JL, Neill BA et al (2008) Prolonged interleukin-6 administration enhances glucose tolerance and increases skeletal muscle PPARalpha and UCP2 expression in rats. J Endocrinol 198:367–374CrossRefPubMed
15.
go back to reference Sadagurski M, Norquay L, Farhang J, D'Aquino K, Copps K, White MF (2010) Human IL6 enhances leptin action in mice. Diabetologia 53:525–535CrossRefPubMed Sadagurski M, Norquay L, Farhang J, D'Aquino K, Copps K, White MF (2010) Human IL6 enhances leptin action in mice. Diabetologia 53:525–535CrossRefPubMed
16.
go back to reference Wallenius V, Wallenius K, Ahren B et al (2002) Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8:75–79CrossRefPubMed Wallenius V, Wallenius K, Ahren B et al (2002) Interleukin-6-deficient mice develop mature-onset obesity. Nat Med 8:75–79CrossRefPubMed
17.
go back to reference Di Gregorio GB, Hensley L, Lu T, Ranganathan G, Kern PA (2004) Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity. Am J Physiol Endocrinol Metab 287:E182–E187CrossRefPubMed Di Gregorio GB, Hensley L, Lu T, Ranganathan G, Kern PA (2004) Lipid and carbohydrate metabolism in mice with a targeted mutation in the IL-6 gene: absence of development of age-related obesity. Am J Physiol Endocrinol Metab 287:E182–E187CrossRefPubMed
18.
go back to reference Kopf M, Baumann H, Freer G et al (1994) Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368:339–342CrossRefPubMed Kopf M, Baumann H, Freer G et al (1994) Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368:339–342CrossRefPubMed
19.
go back to reference Chung J, Nguyen AK, Henstridge DC et al (2008) HSP72 protects against obesity-induced insulin resistance. Proc Natl Acad Sci USA 105:1739–1744CrossRefPubMed Chung J, Nguyen AK, Henstridge DC et al (2008) HSP72 protects against obesity-induced insulin resistance. Proc Natl Acad Sci USA 105:1739–1744CrossRefPubMed
20.
go back to reference Watt MJ, Dzamko N, Thomas WG et al (2006) CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. Nat Med 12:541–548CrossRefPubMed Watt MJ, Dzamko N, Thomas WG et al (2006) CNTF reverses obesity-induced insulin resistance by activating skeletal muscle AMPK. Nat Med 12:541–548CrossRefPubMed
21.
go back to reference Mootha VK, Lindgren CM, Eriksson KF et al (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267–273CrossRefPubMed Mootha VK, Lindgren CM, Eriksson KF et al (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267–273CrossRefPubMed
22.
go back to reference Subramanian A, Tamayo P, Mootha VK et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545–15550CrossRefPubMed Subramanian A, Tamayo P, Mootha VK et al (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545–15550CrossRefPubMed
23.
go back to reference Bruce CR, Hoy AJ, Turner N et al (2009) Overexpression of carnitine palmitoyltransferase-1 in skeletal muscle is sufficient to enhance fatty acid oxidation and improve high-fat diet-induced insulin resistance. Diabetes 58:550–558CrossRefPubMed Bruce CR, Hoy AJ, Turner N et al (2009) Overexpression of carnitine palmitoyltransferase-1 in skeletal muscle is sufficient to enhance fatty acid oxidation and improve high-fat diet-induced insulin resistance. Diabetes 58:550–558CrossRefPubMed
24.
go back to reference Solinas G, Naugler W, Galimi F, Lee MS, Karin M (2006) Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates. Proc Natl Acad Sci USA 103:16454–16459CrossRefPubMed Solinas G, Naugler W, Galimi F, Lee MS, Karin M (2006) Saturated fatty acids inhibit induction of insulin gene transcription by JNK-mediated phosphorylation of insulin-receptor substrates. Proc Natl Acad Sci USA 103:16454–16459CrossRefPubMed
25.
go back to reference Yuan M, Konstantopoulos N, Lee J et al (2001) Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293:1673–1677CrossRefPubMed Yuan M, Konstantopoulos N, Lee J et al (2001) Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293:1673–1677CrossRefPubMed
26.
go back to reference Hirosumi J, Tuncman G, Chang L et al (2002) A central role for JNK in obesity and insulin resistance. Nature 420:333–336CrossRefPubMed Hirosumi J, Tuncman G, Chang L et al (2002) A central role for JNK in obesity and insulin resistance. Nature 420:333–336CrossRefPubMed
27.
go back to reference Lam TK, Yoshii H, Haber CA et al (2002) Free fatty acid-induced hepatic insulin resistance: a potential role for protein kinase C-delta. Am J Physiol Endocrinol Metab 283:E682–E691PubMed Lam TK, Yoshii H, Haber CA et al (2002) Free fatty acid-induced hepatic insulin resistance: a potential role for protein kinase C-delta. Am J Physiol Endocrinol Metab 283:E682–E691PubMed
28.
go back to reference Kim JK, Fillmore JJ, Sunshine MJ et al (2004) PKC-theta knockout mice are protected from fat-induced insulin resistance. J Clin Invest 114:823–827PubMed Kim JK, Fillmore JJ, Sunshine MJ et al (2004) PKC-theta knockout mice are protected from fat-induced insulin resistance. J Clin Invest 114:823–827PubMed
29.
go back to reference Nadler ST, Stoehr JP, Schueler KL, Tanimoto G, Yandell BS, Attie AD (2000) The expression of adipogenic genes is decreased in obesity and diabetes mellitus. Proc Natl Acad Sci USA 97:11371–11376CrossRefPubMed Nadler ST, Stoehr JP, Schueler KL, Tanimoto G, Yandell BS, Attie AD (2000) The expression of adipogenic genes is decreased in obesity and diabetes mellitus. Proc Natl Acad Sci USA 97:11371–11376CrossRefPubMed
30.
go back to reference Feve B, Bastard JP (2009) The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 5:305–311CrossRefPubMed Feve B, Bastard JP (2009) The role of interleukins in insulin resistance and type 2 diabetes mellitus. Nat Rev Endocrinol 5:305–311CrossRefPubMed
31.
go back to reference Febbraio MA, Rose-John S, Pedersen BK (2010) Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases? Clin Pharmacol Ther 87:396–398CrossRefPubMed Febbraio MA, Rose-John S, Pedersen BK (2010) Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases? Clin Pharmacol Ther 87:396–398CrossRefPubMed
32.
go back to reference Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK (2003) Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J 17:884–886PubMed Starkie R, Ostrowski SR, Jauffred S, Febbraio M, Pedersen BK (2003) Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J 17:884–886PubMed
33.
go back to reference Fosgerau K, Galle P, Hansen T et al (2010) Interleukin-6 autoantibodies are involved in the pathogenesis of a subset of type 2 diabetes. J Endocrinol 204:265–273CrossRefPubMed Fosgerau K, Galle P, Hansen T et al (2010) Interleukin-6 autoantibodies are involved in the pathogenesis of a subset of type 2 diabetes. J Endocrinol 204:265–273CrossRefPubMed
34.
35.
go back to reference Garcia MC, Wernstedt I, Berndtsson A et al (2006) Mature-onset obesity in interleukin-1 receptor I knockout mice. Diabetes 55:1205–1213CrossRefPubMed Garcia MC, Wernstedt I, Berndtsson A et al (2006) Mature-onset obesity in interleukin-1 receptor I knockout mice. Diabetes 55:1205–1213CrossRefPubMed
36.
go back to reference Henkel J, Neuschafer-Rube F, Pathe-Neuschafer-Rube A, Puschel GP (2009) Aggravation by prostaglandin E2 of interleukin-6-dependent insulin resistance in hepatocytes. Hepatology 50:781–790CrossRefPubMed Henkel J, Neuschafer-Rube F, Pathe-Neuschafer-Rube A, Puschel GP (2009) Aggravation by prostaglandin E2 of interleukin-6-dependent insulin resistance in hepatocytes. Hepatology 50:781–790CrossRefPubMed
37.
go back to reference Senn JJ, Klover PJ, Nowak IA, Mooney RA (2002) Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51:3391–3399CrossRefPubMed Senn JJ, Klover PJ, Nowak IA, Mooney RA (2002) Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51:3391–3399CrossRefPubMed
38.
go back to reference Cai D, Yuan M, Frantz DF et al (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11:183–190CrossRefPubMed Cai D, Yuan M, Frantz DF et al (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11:183–190CrossRefPubMed
39.
go back to reference Klover PJ, Clementi AH, Mooney RA (2005) Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 146:3417–3427CrossRefPubMed Klover PJ, Clementi AH, Mooney RA (2005) Interleukin-6 depletion selectively improves hepatic insulin action in obesity. Endocrinology 146:3417–3427CrossRefPubMed
40.
go back to reference Franckhauser S, Elias I, Rotter Sopasakis V et al (2008) Overexpression of Il6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice. Diabetologia 51:1306–1316CrossRefPubMed Franckhauser S, Elias I, Rotter Sopasakis V et al (2008) Overexpression of Il6 leads to hyperinsulinaemia, liver inflammation and reduced body weight in mice. Diabetologia 51:1306–1316CrossRefPubMed
41.
go back to reference Cressman DE, Greenbaum LE, DeAngelis RA et al (1996) Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 274:1379–1383CrossRefPubMed Cressman DE, Greenbaum LE, DeAngelis RA et al (1996) Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 274:1379–1383CrossRefPubMed
42.
go back to reference Park EJ, Lee JH, Yu GY et al (2010) Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140:197–208CrossRefPubMed Park EJ, Lee JH, Yu GY et al (2010) Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140:197–208CrossRefPubMed
43.
go back to reference Morino K, Petersen KF, Shulman GI (2006) Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 55(Suppl 2):S9–S15CrossRefPubMed Morino K, Petersen KF, Shulman GI (2006) Molecular mechanisms of insulin resistance in humans and their potential links with mitochondrial dysfunction. Diabetes 55(Suppl 2):S9–S15CrossRefPubMed
44.
go back to reference Patti ME, Butte AJ, Crunkhorn S et al (2003) Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci USA 100:8466–8471CrossRefPubMed Patti ME, Butte AJ, Crunkhorn S et al (2003) Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: potential role of PGC1 and NRF1. Proc Natl Acad Sci USA 100:8466–8471CrossRefPubMed
45.
go back to reference Petersen KF, Befroy D, Dufour S et al (2003) Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300:1140–1142CrossRefPubMed Petersen KF, Befroy D, Dufour S et al (2003) Mitochondrial dysfunction in the elderly: possible role in insulin resistance. Science 300:1140–1142CrossRefPubMed
46.
go back to reference Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI (2004) Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350:664–671CrossRefPubMed Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI (2004) Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med 350:664–671CrossRefPubMed
47.
go back to reference Kim JA, Wei Y, Sowers JR (2008) Role of mitochondrial dysfunction in insulin resistance. Circ Res 102:401–414CrossRefPubMed Kim JA, Wei Y, Sowers JR (2008) Role of mitochondrial dysfunction in insulin resistance. Circ Res 102:401–414CrossRefPubMed
48.
go back to reference Perez-Carreras M, Del Hoyo P, Martin MA et al (2003) Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 38:999–1007PubMed Perez-Carreras M, Del Hoyo P, Martin MA et al (2003) Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 38:999–1007PubMed
50.
go back to reference Jin X, Zhang Z, Beer-Stolz D, Zimmers TA, Koniaris LG (2007) Interleukin-6 inhibits oxidative injury and necrosis after extreme liver resection. Hepatology 46:802–812CrossRefPubMed Jin X, Zhang Z, Beer-Stolz D, Zimmers TA, Koniaris LG (2007) Interleukin-6 inhibits oxidative injury and necrosis after extreme liver resection. Hepatology 46:802–812CrossRefPubMed
Metadata
Title
Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance
Authors
V. B. Matthews
T. L. Allen
S. Risis
M. H. S. Chan
D. C. Henstridge
N. Watson
L. A. Zaffino
J. R. Babb
J. Boon
P. J. Meikle
J. B. Jowett
M. J. Watt
J.-O. Jansson
C. R. Bruce
M. A. Febbraio
Publication date
01-11-2010
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 11/2010
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-010-1865-y

Other articles of this Issue 11/2010

Diabetologia 11/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.